Glaxosmithkline
Clinical trials sponsored by Glaxosmithkline, explained in plain language.
A global pharmaceutical company developing vaccines and specialty medicines.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can a pill replace EPO shots for anemia in kidney disease?
Disease control TerminatedThis trial is testing an experimental oral drug, GSK1278863, in people on dialysis who have anemia due to chronic kidney disease and who don't respond well to standard erythropoietin (EPO) injections. The goal is to see if the drug can raise or maintain hemoglobin levels within a…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug combo enters human trials
Disease control TerminatedThis early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Hepatitis b drug combo trial halted early
Disease control TerminatedThis early-stage study tested a new experimental drug called GSK3965193, alone and in combination with another drug (bepirovirsen), for people with chronic hepatitis B. The goal was to see if the combination could lower hepatitis B virus levels and possibly lead to a sustained re…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eczema drug study halted early: what we learned about GSK1070806
Disease control TerminatedThis study was designed to check the long-term safety of an experimental drug called GSK1070806 for people with moderate to severe eczema (atopic dermatitis). It enrolled 79 adults who had already completed an earlier study of the same drug. The study was terminated early, so res…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Eczema drug trial halted midway – what happened?
Disease control TerminatedThis study tested an injectable drug called GSK1070806 in 161 adults with moderate to severe atopic dermatitis (eczema) who had already tried other treatments. The goal was to see if the drug could reduce eczema severity and itching compared to a placebo. However, the trial was t…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for lung scarring? trial of GSK3915393 cut short
Disease control TerminatedThis study tested a new medicine, GSK3915393, in 158 people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The goal was to see if the drug could slow lung function decline compared to a placebo. The trial was termin…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New vaccine aims to tame hepatitis b in patients on antivirals
Disease control TerminatedThis study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could safely lower hepatitis B surface antigen levels and possibly allow…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Cancer drug combo trial for kids halted early
Disease control TerminatedThis early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumo…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Sickle cell drug candidate tested in first human trial – but study halted early
Disease control TerminatedThis was a first-in-human study testing a single dose of an experimental drug called GSK4172239D in 11 people with sickle cell disease. The main goals were to check safety and how the drug moves through the body. The study was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug aimed at easing diabetic nerve pain hits roadblock
Symptom relief TerminatedThis study tested an experimental drug called GSK3858279 in 147 adults with chronic nerve pain from diabetes. The goal was to see if it could reduce pain better than a placebo. However, the trial was terminated early, so we have less information than planned.
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
New drug aimed at easing knee pain fails to finish trial
Symptom relief TerminatedThis study tested an experimental drug called GSK3858279 in 314 adults with moderate to severe knee osteoarthritis pain. The goal was to find the best dose that reduces pain safely. However, the trial was stopped early, so we have less information than planned.
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Leishmaniasis drug candidate tested in humans for first time – study halted early
Knowledge-focused TerminatedThis was a first-in-human study to check the safety and how the body processes a single dose of GSK3494245, a potential treatment for leishmaniasis. It involved 59 healthy adults who received up to three increasing doses of the drug or a placebo. The study was terminated early, s…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC